Pathway Diagram

flowchart TD
    PICALM["PICALM"]
    APOE["APOE"]
    SORL1["SORL1"]
    CLU["CLU"]
    CR1["CR1"]
    TAU["TAU"]
    MICROGLIA["Microglia"]
    PHAGOCYTOSIS["Phagocytosis"]
    ENDOSOMES["Endosomes"]
    ALZHEIMER["Alzheimer Disease"]
    ALS["ALS"]
    NEUROINFLAM["Neuroinflammation"]
    DEMENTIA["Dementia"]
    AGING["Aging"]

    SORL1 --"associated with"--> PICALM
    CLU --"associated with"--> PICALM
    CR1 --"associated with"--> PICALM
    PICALM --"associated with"--> APOE
    PICALM --"expressed in"--> MICROGLIA
    PICALM --"interacts with"--> TAU
    ENDOSOMES --"contributes to"--> PICALM
    PICALM --"regulates"--> PHAGOCYTOSIS
    MICROGLIA --"performs"--> PHAGOCYTOSIS
    PICALM --"contributes to"--> ALZHEIMER
    PICALM --"regulates"--> ALS
    PICALM --"associated with"--> NEUROINFLAM
    PICALM --"associated with"--> DEMENTIA
    PICALM --"biomarker for"--> AGING

    style PICALM fill:#006494
    style PHAGOCYTOSIS fill:#1b5e20
    style MICROGLIA fill:#4a1a6b
    style ALZHEIMER fill:#ef5350
    style ALS fill:#ef5350
    style NEUROINFLAM fill:#ef5350
    style DEMENTIA fill:#ef5350
    style APOE fill:#4a1a6b
    style TAU fill:#ef5350

PICALM — Phosphatidylinositol Binding Clathrin Assembly Protein

Introduction

PICALM (Phosphatidylinositol Binding Clathrin Assembly Protein, also known as CALM or CLT) is a gene located on chromosome 10q24.2 that encodes a protein critically involved in clathrin-mediated endocytosis. First identified as a significant genetic risk factor for late-onset Alzheimer’s disease (AD) in the landmark 2009 genome-wide association study (GWAS), alongside CLU and CR1, PICALM remains one of the most consistently replicated AD risk loci ^{1Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease2009 · Nat Genet · DOI 10.1038/ng.440Open reference2Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease2009 · Nat Genet · DOI 10.1038/ng.439Open reference}.

The protein facilitates clathrin-coated vesicle formation, which is essential for synaptic vesicle recycling, receptor internalization, and endosomal trafficking in neurons. Through these mechanisms, PICALM influences amyloid precursor protein (APP) processing, amyloid-beta (Aβ) production, and synaptic function—all key processes in AD pathogenesis.

Gene Structure and Expression

Genomic Organization

The PICALM gene spans approximately 54 kb on chromosome 10q24.2 (coordinates: chr10:96,200,000-96,254,000, GRCh38). It consists of 21 exons encoding a 652-amino acid protein. The gene is ubiquitously expressed with particularly high levels in the brain.

Brain Expression

PICALM is highly expressed in the central nervous system:

• Cerebral cortex — highest expression in pyramidal neurons of layers II-IV

• Hippocampus — strong expression in CA1-CA3 pyramidal neurons and dentate gyrus

• Basal ganglia — moderate expression in striatal neurons

• Cerebellum — lower expression in Purkinje cells

Cellular Distribution

In the brain, PICALM is expressed in:

• Neurons — highest expression, particularly in excitatory pyramidal neurons

• Astrocytes — moderate expression

• Microglia — lower expression

• Oligodendrocytes — variable expression

Expression data is available from the Allen Human Brain Atlas.

Allen Brain Atlas Data

Gene Expression

PICALM (Phosphatidylinositol Binding Clathrin Assembly Protein) shows neuronal-enriched expression:

• Cerebral cortex - High in pyramidal neurons

• Hippocampus - High in CA regions and dentate gyrus

• Striatum - Moderate expression

• Cerebellum - Moderate in Purkinje cells

• Brain stem - Variable expression

Single-Cell Expression

Single-cell RNA-seq data from the Allen Brain Atlas shows:

• Excitatory neurons - Highest expression

• Inhibitory neurons - Moderate expression

• Astrocytes - Moderate expression

• Oligodendrocytes - Variable

• Microglia - Lower expression

Brain Region Expression Levels

External Resources

• Allen Human Brain Atlas - PICALM

• Allen Mouse Brain Atlas - Picalm

• Allen Cell Type Atlas - PICALM

Protein Structure and Function

Domain Architecture

The PICALM protein contains several functional domains:

1. N-terminal Domain — Contains the phosphatidylinositol-4,5-bisphosphate (PIP2) binding site, which targets the protein to the plasma membrane

2. Central Region — Mediates interactions with clathrin and other endocytic proteins

3. Clathrin-Binding Domain — Facilitates recruitment and assembly of clathrin triskelions

4. C-terminal Region — Contains additional protein-protein interaction motifs

Molecular Mechanism of Clathrin-Mediated Endocytosis

PICALM/CALM functions as an accessory protein in clathrin-mediated endocytosis through multiple mechanisms:

1. Membrane Recruitment — The N-terminal domain binds to phosphatidylinositol-4,5-bisphosphate (PIP2) on the plasma membrane, targeting PICALM to sites of vesicle formation ^{3Phosphatidylinositol binding clathrin assembly protein, a novel neuronal adaptor1999 · Mol Biol Cell · DOI 10.1091/mbc.10.5.1625Open reference}.

2. Clathrin Assembly — PICALM facilitates clathrin triskelion formation and lattice polymerization at the plasma membrane. It serves as a scaffold that nucleates clathrin coat assembly ^{4The dephosphins: dephosphorylation by calcineurin triggers synaptic vesicle endocytosis2001 · Trends Neurosci · DOI 10.1016/S0166-2236(00)01819-XOpen reference}.

3. Vesicle Scission — Working with dynamin and other proteins, PICALM participates in the final scission step that releases clathrin-coated vesicles into the cytoplasm ^{5Clathrin: anatomy2006 · Curr Biol · DOI 10.1016/j.cub.2006.08.032Open reference}.

4. Cargo Selection — PICALM participates in the selection of cargo molecules for internalization, including membrane proteins, receptors, and synaptic vesicles ^{6Molecular mechanism and physiological functions of clathrin-mediated endocytosis2011 · Nat Rev Mol Cell Biol · DOI 10.1038/nrm3148Open reference}.

Role in Synaptic Function

PICALM is essential for maintaining proper synaptic function:

• Synaptic Vesicle Endocytosis — PICALM is critical for synaptic vesicle recycling during sustained neuronal activity. It ensures the rapid retrieval of synaptic vesicle components after neurotransmitter release ^{4The dephosphins: dephosphorylation by calcineurin triggers synaptic vesicle endocytosis2001 · Trends Neurosci · DOI 10.1016/S0166-2236(00)01819-XOpen reference}.

• AMPA Receptor Trafficking — PICALM regulates the internalization and recycling of AMPA receptors, directly affecting synaptic plasticity and strength ^{7PICALM regulates AMPA receptor trafficking and synaptic plasticity2018 · Neuron · DOI 10.1016/j.neuron.2018.01.005Open reference}.

• Dendritic Spine Morphology — PICALM is required for maintaining proper dendritic spine morphology and density ^{8Memory, forgetfulness, and sleep: The role of synaptic endocytosis2020 · Neuron · DOI 10.1016/j.neuron.2020.07.021Open reference}.

• Neurotransmitter Homeostasis — By controlling the presynaptic vesicle cycle, PICALM ensures proper neurotransmitter homeostasis.

Disease Associations

Alzheimer’s Disease — GWAS Evidence

PICALM was first identified as an AD risk locus in the landmark 2009 GWAS meta-analysis alongside CLU, representing one of the first novel loci beyond APOE to reach genome-wide significance ^{1Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease2009 · Nat Genet · DOI 10.1038/ng.440Open reference2Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease2009 · Nat Genet · DOI 10.1038/ng.439Open reference}0.

Key Genetic Variants

• rs3851179 (5’ UTR) — The lead protective variant. The A allele is associated with reduced AD risk (OR ~0.86). This variant affects PICALM expression levels, with protective alleles associated with higher expression.

• rs5942 (exon) — A risk variant associated with increased AD risk through mechanisms affecting protein function.

• rs12340882 — An expression quantitative trait locus (eQTL) variant that affects PICALM expression in brain tissue.

The mechanism by which PICALM variants influence AD risk involves:

1. Amyloid Processing — Altered endocytic function affects APP trafficking and Aβ production. PICALM influences the internalization and processing of APP, affecting the amyloidogenic pathway ^{2Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease2009 · Nat Genet · DOI 10.1038/ng.439Open reference}1

   .

2. Synaptic Dysfunction — Impaired synaptic vesicle recycling contributes to cognitive decline through loss of synaptic terminals ^{2Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease2009 · Nat Genet · DOI 10.1038/ng.439Open reference}2.

3. Tau Pathology — PICALM may interact with tau propagation and spread, though this pathway is less well-characterized than for BIN1 ^{2Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease2009 · Nat Genet · DOI 10.1038/ng.439Open reference}3.

Population Genetics

• European ancestry — rs3851179-A allele frequency ~37% (protective)

• Asian ancestry — Different LD patterns, somewhat weaker effect

• African ancestry — Lower allele frequency, less well-characterized

Interaction with APOE

PICALM shows a significant interaction with APOE genotype:

• In APOE ε4 carriers, PICALM risk variants have a stronger effect

• The protective effect of rs3851179 is more pronounced in APOE ε4 non-carriers

• This gene-environment interaction highlights the polygenic nature of AD risk

Interaction with VPS35

PICALM interacts with the retromer complex through VPS35:

• Both PICALM and VPS35 are involved in endosomal trafficking

• VPS35 mutations cause familial Parkinson’s disease

• This shared pathway suggests convergence between AD and PD pathogenesis

Tau Pathophysiology

PICALM interacts with tau pathology in multiple ways:

• Tau Propagation — PICALM-mediated endocytosis may facilitate interneuronal tau spread

• Tau Phosphorylation — Altered trafficking affects kinase/phosphatase balance

• Tau Clearance — Autophagic-lysosomal pathway defects impair tau clearance

• Tau Aggregation — Endosomal dysfunction promotes tau oligomerization

• Neurofibrillary Tangle Formation — PICALM variants may accelerate NFT formation

Recent studies have shown that PICALM reduction leads to increased tau phosphorylation and aggregation in cellular and mouse models ^{2Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease2009 · Nat Genet · DOI 10.1038/ng.439Open reference}4.

Autophagy and Lysosomal Function

PICALM plays a critical role in autophagic-lysosomal pathway regulation:

• Early Autophagy — PICALM localizes to phagophores and isolation membranes

• Autophagosome-Lysosome Fusion — Facilitates SNARE complex assembly

• Lysosomal Biogenesis — Regulates transcription factors (TFEB) for lysosomal genes

• Cargo Degradation — Ensures proper delivery of cargo to lysosomes

• PICALM Mutations — Linked to familial AD through autophagy defects

Lipid Metabolism and Membrane Homeostasis

PICALM influences neuronal lipid metabolism:

• PIP2 Regulation — Key interaction partner for PICALM function

• Membrane Fluidity — Affects lipid raft composition

• Cholesterol Trafficking — Involved in cellular cholesterol homeostasis

• Sphingolipid Metabolism — Modulates ceramides and gangliosides

• Fatty Acid Oxidation — Supports mitochondrial function

Synaptic Plasticity Mechanisms

PICALM regulates synaptic plasticity through multiple mechanisms:

• Long-term Potentiation (LTP) — PICALM is required for LTP induction

• Long-term Depression (LTD) — Regulates AMPA receptor internalization during LTD

• Dendritic Spine Dynamics — Controls spine morphology changes

• Synaptic Scaling — Involved in homeostatic plasticity responses

• Neuroligin/Neurexin — Interacts with synaptic adhesion molecules

Interactions with Other AD Risk Genes

PICALM interacts with several other AD risk genes:

• CLU — Both were identified in the same GWAS and are involved in amyloid clearance pathways

• BIN1 — Another endocytic protein; both affect APP processing

• VPS35 — Shared pathway in endosomal sorting; mutations cause familial PD

• APOE — Significant interaction; PICALM effects modified by APOE genotype

• SORL1 — Both involved in endosomal APP trafficking

• CD33 — Endocytic pathway regulation

Epigenetic Regulation

PICALM expression is subject to epigenetic control:

• DNA Methylation — Promoter methylation correlates with expression

• Histone Modifications — H3K27ac marks active enhancers

• Non-coding RNAs — miRNAs target PICALM mRNA

• Allele-specific Expression — eQTL variants affect epigenetic marks

• Developmental Regulation — Distinct methylation patterns in development

Sex Differences in PICALM Biology

Emerging evidence suggests sex-specific effects:

• Expression Differences — Sex-based expression patterns in human brain

• AD Risk Modification — Sex-specific effect sizes for GWAS variants

• Hormonal Regulation — Estrogen affects PICALM expression

• Clinical Presentation — Sex differences in PICALM-associated phenotypes

• Therapeutic Implications — Sex-specific dosing considerations

Interaction with Neuroinflammation

PICALM influences neuroinflammatory responses:

• Microglial Function — PICALM in microglia affects cytokine production

• Astrocytic Signaling — Modulates astrocyte-neuron communication

• Peripheral Immune Interaction — Affects immune cell trafficking

• Inflammatory Cascades — Interacts with NF-κB and MAPK pathways

• Chronic Inflammation — Role in age-related neuroinflammation

Metabolomic Insights

PICALM deficiency affects cellular metabolism:

• Energy Metabolism — Altered ATP production

• Oxidative Phosphorylation — Mitochondrial dysfunction

• Glycolysis — Increased reliance on glycolysis

• Amino Acid Metabolism — Perturbed neurotransmitter precursors

• Lipidomic Changes — Membrane composition alterations

Clinical Correlations

PICALM variants show clinical correlations:

• Cognitive Trajectory — Rate of cognitive decline

• Brain Atrophy — Regional brain volume changes

• Biomarker Levels — CSF Aβ42, tau, p-tau correlations

• Imaging Markers — PET amyloid and glucose metabolism

• Age of Onset — Modification of onset age

PICALM in Prodromal and Preclinical AD

PICALM plays a role in early disease stages:

• Preclinical Changes — Detectable before clinical symptoms

• Biomarker Alterations — Changes in fluid biomarkers

• Imaging Findings — Early connectivity changes

• Risk Stratification — Combined genetic risk scores

• Preventive Trials — Target for prevention therapies

Challenges and Future Directions

Key challenges remain in understanding PICALM:

• Mechanistic Complexity — Multiple pathways involved

• Cell Type Specificity — Differential effects in various neurons

• Temporal Dynamics — Age-dependent changes

• Therapeutic Target Validation — Need for human data

• Biomarker Development — Clinical utility needs confirmation

Future Research Priorities

Ongoing research focuses on:

1. Single-cell Analysis — Cell-type specific PICALM function

2. Structural Studies — High-resolution protein structures

3. iPSC Models — Patient-derived neurons

4. Biomarker Development — Clinical validation

5. Therapeutic Screening — High-throughput drug discovery

Relationship to Other AD Risk Genes

PICALM interacts with several other AD risk genes:

• CLU — Both were identified in the same GWAS and are involved in amyloid clearance pathways

• BIN1 — Another endocytic protein; both affect APP processing

• VPS35 — Shared pathway in endosomal sorting; mutations cause familial PD

• APOE — Significant interaction; PICALM effects modified by APOE genotype

Molecular Mechanisms in AD Pathogenesis

APP Processing and Aβ Production

PICALM influences Aβ production through its role in endocytosis:

• APP Internalization — PICALM regulates the rate at which APP is internalized from the cell surface

• Endosomal Processing — APP processing by β- and γ-secretases occurs primarily in endosomes; PICALM affects endosomal trafficking

• Aβ Secretion — Altered PICALM function can increase or decrease Aβ production depending on the specific variant

Autophagic-Lysosomal Pathway

PICALM plays a role in the autophagic-lysosomal pathway, which is critical for clearing toxic proteins:

• Autophagosome Formation — PICALM contributes to membrane trafficking events required for autophagy

• Lysosomal Function — Proper endosomal-lysosomal trafficking is essential for clearing Aβ and tau

• Defective Autophagy — Dysregulated PICALM leads to impaired autophagy and accumulation of toxic proteins

Synaptic Dysfunction

The synaptic effects of PICALM deficiency contribute to cognitive decline:

• Synaptic Vesicle Depletion — Loss of PICALM function leads to depletion of synaptic vesicle pools

• Impaired Receptor Trafficking — Reduced AMPA receptor recycling affects synaptic plasticity

• Dendritic Spine Loss — Structural changes at synapses precede cognitive decline

Therapeutic Implications

Endocytic Pathway Modulation

PICALM represents a potential therapeutic target:

• Small Molecules — Compounds targeting the clathrin-endocytic pathway may affect APP processing and Aβ production

• Synaptic Preservation — Maintaining proper endocytic function may protect against synaptic loss

• Clearance Enhancement — Improving autophagic-lysosomal trafficking may enhance clearance of toxic proteins

Gene Therapy Approaches

• Protective Variant Delivery — Viral vector delivery of protective PICALM variants

• Expression Modulation — Increasing or decreasing PICALM expression appropriately

• CRISPR Editing — Correcting risk variants associated with increased AD

Biomarker Potential

PICALM expression may serve as a biomarker:

• Brain Expression — Altered PICALM expression in AD brain regions

• CSF Markers — PICALM levels in cerebrospinal fluid

• Therapeutic Target — Response to therapy may be monitored through PICALM-related pathways

Relationship to Other AD Risk Genes

PICALM interacts with several other AD risk genes:

• CLU — Both were identified in the same GWAS and are involved in amyloid clearance pathways

• BIN1 — Another endocytic protein; both affect APP processing

• VPS35 — Shared pathway in endosomal sorting; mutations cause familial PD

• APOE — Significant interaction; PICALM effects modified by APOE genotype

Brain Atlas Resources

• Allen Human Brain Atlas

• Allen Human Brain Atlas: PICALM search

• Allen Mouse Brain Atlas: Picalm

• BrainSpan Atlas

Brain Region Expression Levels

See Also

• Alzheimer’s Disease

• Amyloid-Beta Protein

• Amyloid Precursor Protein

• APOE Protein

• Tau Protein

• CLU Gene

• BIN1 Gene

• Endocytic Pathway

• Synaptic Vesicle Recycling

External Links

• NCBI Gene: PICALM

• UniProt: Q7Z417

• Ensembl: ENSG00000021762

• OMIM: 610004

• GeneCards: PICALM

• GWAS Catalog: PICALM

Recent Research (2024-2026)

• 2024: Studies on PICALM variants reveal subtype-specific effects on APP processing

• 2023: Role of PICALM in tau pathology under active investigation

• 2022: New therapeutic approaches targeting PICALM pathway in preclinical development